These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1927238)

  • 41. Effects of low doses of lorazepam on psychometric tests in healthy volunteers.
    Bourin M; Couëtoux du Tertre A; Colombel MC; Auget JL
    Int Clin Psychopharmacol; 1994; 9(2):83-8. PubMed ID: 8056998
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the relationship between structure and CNS effects for lorazepam, clonazepam and alprazolam.
    Ellinwood EH; Nikaido AM; Gupta SK; Heatherly DG; Hege S
    J Psychopharmacol; 1993 Jan; 7(1 Suppl):24-32. PubMed ID: 22290367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Psychomotor effects of the anxiolytic abecarnil: a comparison with lorazepam.
    Hege SG; Ellinwood EH; Wilson WH; Helligers CA; Graham SM
    Psychopharmacology (Berl); 1997 May; 131(2):101-7. PubMed ID: 9201796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic benzodiazepine administration. XII. Anticonvulsant cross-tolerance but distinct neurochemical effects of alprazolam and lorazepam.
    Byrnes JJ; Miller LG; Greenblatt DJ; Shader RI
    Psychopharmacology (Berl); 1993; 111(1):91-5. PubMed ID: 7870939
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Effect of Chronic Alprazolam Intake on Memory, Attention, and Psychomotor Performance in Healthy Human Male Volunteers.
    Chowdhury ZS; Morshed MM; Shahriar M; Bhuiyan MA; Islam SM; Bin Sayeed MS
    Behav Neurol; 2016; 2016():3730940. PubMed ID: 27462136
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers.
    Calvo G; García-Gea C; Luque A; Morte A; Dal-Ré R; Barbanoj M
    J Clin Psychopharmacol; 2004 Jun; 24(3):268-76. PubMed ID: 15118480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparative study of the psychological effects of DN-2327, a partial benzodiazepine agonist, and alprazolam.
    Suzuki M; Uchiumi M; Murasaki M
    Psychopharmacology (Berl); 1995 Oct; 121(4):442-50. PubMed ID: 8619007
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A clinical method of evaluating simple reaction time and reaction accuracy is sensitive to a single dose of lorazepam.
    Richardson JK; Eckner JT; Kim H; Ashton-Miller JA
    J Psychopharmacol; 2020 Aug; 34(8):920-925. PubMed ID: 32536331
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state.
    Scavone JM; Greenblatt DJ; Goddard JE; Friedman H; Harmatz JS; Shader RI
    Eur J Clin Pharmacol; 1992; 42(4):439-43. PubMed ID: 1516609
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alprazolam 0.125 mg twice a day improves aspects of psychometric performance in healthy volunteers.
    Bourin M; Colombel MC; Guitton B
    J Clin Psychopharmacol; 1998 Oct; 18(5):364-72. PubMed ID: 9790153
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dose-dependent effects of intravenous lorazepam on cardiovascular activity, plasma catecholamines and psychological function during rest and mental stress.
    Tulen JH; Moleman P; Boomsma F; van Steenis HG; van den Heuij VJ
    Psychopharmacology (Berl); 1991; 105(1):77-83. PubMed ID: 1745715
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic and pharmacodynamic effects of a single nocturnal dose of alprazolam.
    Norman TR; Burrows GD; McIntyre IM
    Int Clin Psychopharmacol; 1990 Apr; 5(2):111-7. PubMed ID: 2199575
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of lorazepam on skin conductance responses to aversive stimuli in healthy subjects.
    Siepmann M; Heine B; Kluge A; Ziemssen T; Mück-Weymann M; Kirch W
    Clin Auton Res; 2007 Jun; 17(3):160-4. PubMed ID: 17390103
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benzodiazepine pharmacodynamics: evidence for biophase rate limiting mechanisms.
    Ellinwood EH; Nikaido AM; Heatherly DG; Bjornsson TD
    Psychopharmacology (Berl); 1987; 91(2):168-74. PubMed ID: 2883695
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of granisetron and lorazepam, alone and in combination, on psychometric performance.
    Leigh TJ; Link CG; Fell GL
    Br J Clin Pharmacol; 1991 Mar; 31(3):333-6. PubMed ID: 1647193
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of BRL 46470A, a novel 5-HT3 receptor antagonist, and lorazepam on psychometric performance and the EEG.
    Link CG; Leigh TJ; Dennison JK
    Br J Clin Pharmacol; 1993 Apr; 35(4):395-9. PubMed ID: 8485019
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Separate and combined psychopharmacological effects of alprazolam and oxycodone in healthy volunteers.
    Zacny JP; Paice JA; Coalson DW
    Drug Alcohol Depend; 2012 Aug; 124(3):274-82. PubMed ID: 22365897
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A study to evaluate the effect of ondansetron on psychomotor performance after repeated oral dosing in healthy subjects.
    Hall ST; Ceuppens PR
    Psychopharmacology (Berl); 1991; 104(1):86-90. PubMed ID: 1679243
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of a benzodiazepine, lorazepam, on motion integration and segmentation: an effect on the processing of line-ends?
    Giersch A; Lorenceau J
    Vision Res; 1999 Jun; 39(11):2017-25. PubMed ID: 10343785
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative study of the abuse liability of alprazolam, lorazepam, diazepam, methaqualone, and placebo.
    Orzack MH; Friedman L; Dessain E; Bird M; Beake B; McEachern J; Cole JO
    Int J Addict; 1988 May; 23(5):449-67. PubMed ID: 3061941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.